がん免疫療法の市場規模、シェア、成長分析、製品タイプ別、用途別、形態別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025～2032年

がん免疫療法市場規模は2023年に1,364億米ドルとなり、2024年の1,486億8,000万米ドルから2032年には2,962億5,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは9.0％で成長する見通しです。

世界のがん免疫療法市場は、ヘルスケア支出の増加、がん罹患率の上昇、医療保険へのアクセス向上、治療技術の進歩などの要因によって、大きな成長が見込まれています。免疫療法は、メラノーマから肺がんまで、さまざまながんと闘う免疫系の能力を強化するもので、従来の治療法に比べて副作用が少なく、長期にわたる予防効果があります。米国国立がん研究所の統計によると、2020年には米国で新たに180万人以上のがん患者が発生するとされており、効果的な治療法の緊急性が強調されています。しかし、市場は厳しい規制の枠組みや高い開発コストのために課題に直面する可能性があり、潜在的に新規参入を制限し、予測期間中にこの分野での全体的な進展を遅らせる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 規制分析

がん免疫療法市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• チェックポイント阻害剤
• モノクローナル抗体
• ワクチン
• 細胞療法
• 免疫調節薬
• 腫瘍溶解性ウイルス

がん免疫療法市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 肺がん
• 乳がん
• 黒色腫
• 多発性骨髄腫
• 前立腺がん
• 卵巣がん
• 子宮頸がん
• 胃がん
• 大腸がん
• 頭頸部がん
• その他

がん免疫療法市場規模：形態別& CAGR（2025-2032）

• 市場概要
• 静脈内（IV）
• 筋肉内
• 経口

がん免疫療法市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 腫瘍学クリニック
• 在宅ケア
• その他

がん免疫療法市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 直接販売
• 小売販売
• 薬局

がん免疫療法市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• AstraZeneca plc（UK）
• Johnson & Johnson（USA）
• Novartis International AG（Switzerland）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Gilead Sciences, Inc.（USA）
• Sanofi（France）
• Regeneron Pharmaceuticals Inc.（USA）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（UK）
• Daiichi Sankyo Company, Limited（Japan）
• Incyte Corporation（USA）

結論と提言

Cancer Immunotherapy Market size was valued at USD 136.4 billion in 2023 and is poised to grow from USD 148.68 billion in 2024 to USD 296.25 billion by 2032, growing at a CAGR of 9.0% during the forecast period (2025-2032).

The global cancer immunotherapy market is poised for significant growth, driven by factors such as increasing healthcare expenditures, rising cancer incidence, improved access to medical insurance, and advancements in treatment technologies. Immunotherapy, which enhances the immune system's ability to combat various cancers-ranging from melanoma to lung cancer-offers long-lasting protection with fewer side effects compared to traditional treatments. Statistics from the National Cancer Institute highlighted that over 1.8 million new cancer cases were diagnosed in the U.S. in 2020, emphasizing the urgent need for effective therapies. However, the market may face challenges due to stringent regulatory frameworks and high development costs, potentially restricting new entrants and slowing overall progress in the sector during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Immunotherapy Market Segments Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, Form, End User, Distribution Channel and region. Based on Product Type, the market is segmented into Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators and Oncolytic Virus. Based on Application, the market is segmented into Lung Cancer,Breast Cancer, Melanoma, Multiple Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer and Others. Based on Form, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Oncology Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Direct Tenders, Retail Sales and Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Immunotherapy Market

The global cancer immunotherapy market is experiencing significant growth, largely driven by the increasing incidence of various types of cancer around the world. The rising rates of conditions such as lung, breast, colorectal, melanoma, and hematological cancers underscore the urgent need for innovative and effective treatment options. As cancer continues to be one of the leading causes of morbidity and mortality globally, the demand for advanced therapeutic solutions is critical. This scenario emphasizes the importance of creating novel strategies that can effectively tackle the escalating challenges posed by cancer, thereby enhancing patient outcomes and overall public health.

Restraints in the Cancer Immunotherapy Market

The cancer immunotherapy market faces significant challenges that hinder its growth. Over the past decade, the rising incidence of cancer has spurred extensive research and development in the field of cancer treatments. However, as the processes of manufacturing and testing immunotherapies become more elaborate, the associated costs for patients have skyrocketed, ultimately limiting market expansion. Additionally, the potential side effects related to immunotherapy-such as swelling, skin rashes, heart palpitations, and other adverse reactions-can deter patients from pursuing these treatments. Consequently, these factors contribute to the constraints affecting the overall growth of the cancer immunotherapy market.

Market Trends of the Cancer Immunotherapy Market

The Cancer Immunotherapy market is experiencing a dynamic shift towards diversified immunotherapy solutions, driven by an increasing global cancer patient population and accelerated advancements in medical research. Recent innovations, such as the novel method developed by researchers at the University of Texas and MD Anderson Cancer Center for extracting immunotherapy drugs through peptide linkages within the human body, signify a critical evolution in drug development. This approach not only enhances the efficacy of treatments but also opens new avenues for personalized cancer therapies, making it a promising trend that is likely to attract significant investment and foster competitive growth within the sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Regulatory Analysis

Global Cancer Immunotherapy Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Checkpoint Inhibitors
• Monoclonal Antibodies
• Vaccines
• Cell Therapies
• Immunomodulators
• Oncolytic Virus

Global Cancer Immunotherapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Multiple Myeloma
• Prostate Cancer
• Ovarian Cancer
• Cervical Cancer
• Stomach Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Others

Global Cancer Immunotherapy Market Size by Form & CAGR (2025-2032)

• Market Overview
• Intravenous (IV)
• Intramuscular
• Oral

Global Cancer Immunotherapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Oncology Clinics
• Homecare
• Others

Global Cancer Immunotherapy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tenders
• Retail Sales
• Pharmacies

Global Cancer Immunotherapy Market Size & CAGR (2025-2032)

• North America (Product Type, Application, Form, End User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Application, Form, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, Form, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, Form, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, Form, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations